• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Obagi Medical Products Introduces CLENZIderm M.D. Acne Therapeutic System for Normal to Dry Skin

Posted on: Monday, 2 July 2007, 09:22 CDT

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, announced today the introduction of the newest addition to its clinically proven line of topical products to treat acne -- CLENZIderm M.D.™ Acne Therapeutic System for Normal to Dry Skin. This simple three-step system, based on Obagi's patent-pending, solubilized benzoyl peroxide, penetrates deep and clears acne fast, while minimizing dryness and maximizing patient comfort.

Clinical studies show that when used just once per day, this therapeutic system reduces the inflammatory lesions by 50% and delivers a 29% reduction in non-inflammatory lesions within two weeks. The system's liquefied benzoyl peroxide is 1/10,000 the average size of other benzoyl peroxide products on the market. CLENZIderm M.D.'s SoluZyl Technology™ enables the powerful antimicrobial benzoyl peroxide to quickly penetrate the pores and begin reducing acne bacteria below the skin's surface to clear acne faster.

When directed by a physician, the system may also be used with other topical acne treatments to alleviate the dry skin irritation those products cause. Clinical studies show that there was no dryness of the skin after three weeks of using the system, and 91% of patients reported a rating of "Very Comfortable" when describing the comfort level of their treated skin after three weeks of use. Since the CLENZIderm system contains no antibiotics, it offers a further benefit to physicians and patients who are concerned about antibiotic resistance.

"We are pleased to introduce another clinically-backed acne therapy system that gives acne patients compelling results and greater patient comfort," said Steve Carlson, Obagi Medical Products' President and CEO. "Now with systems designed for oily to dry skin types, Obagi offers a prescription-strength acne therapeutic system that is right for all acne patients. We think this new system will be readily embraced by physicians as many of their patients suffer from excessively dry and irritated skin when undergoing acne treatment."

The CLENZIderm M.D. Acne Therapeutic System for Normal to Dry Skin consists of three products, a Daily Care Cream Cleanser, a Therapeutic Lotion and a Therapeutic Moisturizer. The Therapeutic Lotion delivers powerful acne-fighting ingredients while the Therapeutic Moisturizer delivers protection, hydration and moisture with 20% glycerin and 1% dimethicone.

Along with the already popular Obagi CLENZIderm M.D. System for Normal to Oily Skin that was introduced last February, this new Normal to Dry Skin System will be available in dermatologist, plastic surgeon, and other select offices nationwide at the beginning of August 2007.

About Obagi Medical Products, Inc. Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi launched its first skincare system, Obagi Nu-Derm in 1988; and in 2004 launched the first and only prescription-strength vitamin C and hydroquinone system, Obagi-C Rx. In 2005, the company launched Obagi Professional-C, a line of highly stable vitamin C serums. In 2006, the company introduced Obagi Nu-Derm Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction. The Company launched its new Obagi ELASTIderm eye skin care and Obagi CLENZIderm M.D. acne therapeutic systems in February 2007. Obagi System products are only available through physicians. Visit www.obagi.com for information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes,""expects,""may,""will,""should,""potential,""anticipates,""plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2006. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.

Source: Business Wire

More News in this Category